Document is current
Any future updates will be listed below
-
Authors
Oh, Mi-Kyung
Park, Hyun Sung
Chae, Dong-Hoon
Yu, Aaron
Park, Jae Han
Heo, Jiyoung
Cho, Keonwoo
Kim, Jiho
Lim, Byeonghwi https://orcid.org/0000-0001-8489-0044
Kim, Jun-Mo
Axelrad, Jordan E.
Jang, Kyung Ku
Im, Jong Pil
Koh, Seong-Joon
Kim, Byung-Soo
Yu, Kyung-Rok
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (RS-2023-00218476)
National Research Foundation of Korea (RS-2022-NR071992)
- License Information
-
More Information
Article History
Received: 30 July 2025
Revised: 16 November 2025
Accepted: 16 November 2025
First Online: 25 December 2025
Competing interests
: J. Axelrad has received research grants from BioFire Diagnostics, Genentech, Janssen, and Takeda, and consultancy fees, honoraria, or advisory board fees from AbbVie, Abivax, Adiso, BioFire Diagnostics, bioMérieux, Bristol Myers Squibb, Celltrion, Ferring, Fresenius, Janssen, Johnson & Johnson, Merck, Pfizer, Sanofi, Takeda, and Vedanta. All other authors declare no competing interests.
